SAPHIR Work Packages
Pillar A: Socio-economic context analysis of the SAPHIR diseases and their control measures.
WP1. Economic analysis of the SAPHIR diseases and their existing control measures, including vaccination.
WP2. Identification of the sociological pathways for SAPHIR diseases.
Pillar B: Development of pathogen-specific vaccine strategies.
WP3. Development of novel adaptable attenuated PRRSV marker vaccines.
WP4. Development of a M. hyopneumoniae attenuated vaccine and improvement of bacterin vaccine.
WP5. Eimeria: understanding protective immunity and development as vaccine vectors.
WP6. The use of Eimeria and Bacillus strains expressing C. perfringens antigens to prevent necrotic enteritis in broilers.
WP7. Development of DIVA BRSV vaccines.
WP8. Development of a M. bovis subunit-vaccine using a reverse vaccinology approach.
Pillar C: Development of generic vaccine strategies.
WP9. Improving vaccine adjuvants by targeted stimulation of dendritic cells.
WP10. New vaccine platforms: new generation of DNA vaccines and viral replicon particles.
WP11. Optimizing mucosal and skin delivery.
WP12. Understanding and improvement of age-dependent vaccines response.
WP13. Individual variability of immunocompetence: search for markers predictive of vaccine responses.
Pillar D: Strategies to translate SAPHIR research into the market and into the field.
WP14. From laboratory to the market (demonstration).
WP15. Socio-economic evaluation of the SAPHIR strategies.
WP16. Prediction of vaccine effectiveness in the field.
Pillar E / WP17: Outreach, dissemination and training.
Pillar F / WP18: Management.
WP1. Economic analysis of the SAPHIR diseases and their existing control measures, including vaccination.
WP2. Identification of the sociological pathways for SAPHIR diseases.
Pillar B: Development of pathogen-specific vaccine strategies.
WP3. Development of novel adaptable attenuated PRRSV marker vaccines.
WP4. Development of a M. hyopneumoniae attenuated vaccine and improvement of bacterin vaccine.
WP5. Eimeria: understanding protective immunity and development as vaccine vectors.
WP6. The use of Eimeria and Bacillus strains expressing C. perfringens antigens to prevent necrotic enteritis in broilers.
WP7. Development of DIVA BRSV vaccines.
WP8. Development of a M. bovis subunit-vaccine using a reverse vaccinology approach.
Pillar C: Development of generic vaccine strategies.
WP9. Improving vaccine adjuvants by targeted stimulation of dendritic cells.
WP10. New vaccine platforms: new generation of DNA vaccines and viral replicon particles.
WP11. Optimizing mucosal and skin delivery.
WP12. Understanding and improvement of age-dependent vaccines response.
WP13. Individual variability of immunocompetence: search for markers predictive of vaccine responses.
Pillar D: Strategies to translate SAPHIR research into the market and into the field.
WP14. From laboratory to the market (demonstration).
WP15. Socio-economic evaluation of the SAPHIR strategies.
WP16. Prediction of vaccine effectiveness in the field.
Pillar E / WP17: Outreach, dissemination and training.
Pillar F / WP18: Management.
